Last reviewed · How we verify
Buspirone HCl
Buspirone HCl is a 5-HT1A receptor agonist Small molecule drug developed by Par Pharmaceutical, Inc.. It is currently FDA-approved for Generalized anxiety disorder. Also known as: Buspar.
Buspirone acts as a serotonin 5-HT1A receptor agonist to reduce anxiety without the sedation or dependence associated with benzodiazepines.
Buspirone acts as a serotonin 5-HT1A receptor agonist to reduce anxiety without the sedation or dependence associated with benzodiazepines. Used for Generalized anxiety disorder.
At a glance
| Generic name | Buspirone HCl |
|---|---|
| Also known as | Buspar |
| Sponsor | Par Pharmaceutical, Inc. |
| Drug class | 5-HT1A receptor agonist |
| Target | 5-HT1A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Buspirone selectively binds to and activates serotonin 5-HT1A receptors in the brain, particularly in the raphe nuclei and limbic system, which modulates serotonergic neurotransmission and reduces anxiety symptoms. Unlike benzodiazepines, it does not enhance GABA inhibition, resulting in minimal sedation, muscle relaxation, or anticonvulsant effects, and carries a low potential for abuse or dependence.
Approved indications
- Generalized anxiety disorder
Common side effects
- Dizziness
- Headache
- Nervousness
- Lightheadedness
- Nausea
Key clinical trials
- Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment (PHASE4)
- Transformation of Paralysis to Stepping (EARLY_PHASE1)
- Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury (PHASE2)
- Buspirone for Anxiety in Autistic Youth (PHASE4)
- Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression (PHASE4)
- Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal (NA)
- Spinal Cord Neuromodulation for Spinal Cord Injury (PHASE1, PHASE2)
- Evaluating Buspirone to Treat Opioid Withdrawal (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Buspirone HCl CI brief — competitive landscape report
- Buspirone HCl updates RSS · CI watch RSS
- Par Pharmaceutical, Inc. portfolio CI
Frequently asked questions about Buspirone HCl
What is Buspirone HCl?
How does Buspirone HCl work?
What is Buspirone HCl used for?
Who makes Buspirone HCl?
Is Buspirone HCl also known as anything else?
What drug class is Buspirone HCl in?
What development phase is Buspirone HCl in?
What are the side effects of Buspirone HCl?
What does Buspirone HCl target?
Related
- Drug class: All 5-HT1A receptor agonist drugs
- Target: All drugs targeting 5-HT1A receptor
- Manufacturer: Par Pharmaceutical, Inc. — full pipeline
- Therapeutic area: All drugs in Psychiatry/Neurology
- Indication: Drugs for Generalized anxiety disorder
- Also known as: Buspar
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing